{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:56:22Z","timestamp":1780404982524,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Nobelpharma Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Clinical evidence is required about the long-term efficacy and safety of melatonin treatment for sleep problems in children with neurodevelopmental disorders (NDDs) who underwent adequate sleep hygiene interventions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a 26-week, multicenter, collaborative, uncontrolled, open-label, phase III clinical trial of melatonin granules in children 6 to 15\u2009years of age who had NDDs and sleep problems. The study consisted of the 2-week screening phase, the 26-week medication phases I and II, and the 2-week follow-up phase. Children received 1, 2, or 4\u2009mg melatonin granules orally in the medication phases. Variables of sleep status including sleep onset latency (SOL), aberrant behaviors listed on the Aberrant Behavior Check List-Japanese version (ABC-J), and safety were examined. The primary endpoint was SOL in the medication phase I.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between June 2016 and July 2018, 99 children (80 males and 19 females, 10.4\u2009years in mean age) were enrolled at 17 medical institutions in Japan\u201474, 60, 22, 9, 6, and 1 of whom had autism spectrum disorder, attention-deficit\/hyperactivity disorder, intellectual disabilities, motor disorders, specific learning disorder, and communication disorders, respectively, at baseline. Fifteen children received the maximal dose of 4\u2009mg among the prespecified dose levels. SOL recorded with the electronic sleep diary shortened significantly (mean\u2009\u00b1\u2009standard deviation [SD], \u2212\u200936.7\u2009\u00b1\u200946.1\u2009min; 95% confidence interval [CI], \u2212\u200945.9 to \u2212\u200927.5;<jats:italic>P<\/jats:italic>\u2009&lt;\u2009\u00a00.0001) in the medication phase I from baseline, and the SOL-shortening effect of melatonin persisted in the medication phase II and the follow-up phase. Temper upon wakening and sleepiness after awakening improved significantly (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009\u00a00.0001 each) in the medication phase I from baseline and persisted in the follow-up phase. The following subscales of the ABC-J improved significantly: stereotypic behavior (<jats:italic>P<\/jats:italic>\u2009=\u20090.0322) in the medication phase I; and irritability, hyperactivity, and inappropriate speech (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009\u00a00.0001) in the medication phase II. Treatment-emergent adverse events did not occur subsequent to week 16 after medication onset, and NDDs did not deteriorate in the follow-up phase.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Long-term melatonin treatment in combination with adequate sleep hygiene interventions may afford clinical benefits to children with NDDs and potentially elevates their well-being.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrils.gov\">ClinicalTrils.gov<\/jats:ext-link>,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02757066\">NCT02757066<\/jats:ext-link>. Registered April 27, 2016.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12888-020-02847-y","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T04:04:07Z","timestamp":1599710647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Long-term melatonin treatment for the sleep problems and aberrant behaviors of children with neurodevelopmental disorders"],"prefix":"10.1186","volume":"20","author":[{"given":"Kotaro","family":"Yuge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Nagamitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Sugioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Yotsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushiro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"issue":"3","key":"2847_CR1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2174\/1570159X14666161228122115","volume":"15","author":"S Tordjman","year":"2017","unstructured":"Tordjman S, Chokron S, Delorme R, Charrier A, Bellissant E, Jaafari N, et al. Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol. 2017;15(3):434\u201343.","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"2847_CR2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1056\/NEJM199701163360306","volume":"336","author":"A Brzezinski","year":"1997","unstructured":"Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336(3):186\u201395..","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"2847_CR3","first-page":"19","volume":"57","author":"M Karasek","year":"2006","unstructured":"Karasek M, Winczyk K. Melatonin in humans. J Physiol Pharmacol. 2006;57(Suppl 5):19\u201339.","journal-title":"J Physiol Pharmacol"},{"issue":"4","key":"2847_CR4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/0748730405277492","volume":"20","author":"J Arendt","year":"2005","unstructured":"Arendt J. Melatonin: characteristics, concerns, and prospects. J Biol Rhythm. 2005;20(4):291\u2013303.","journal-title":"J Biol Rhythm"},{"issue":"2","key":"2847_CR5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1651-2227.2000.tb01220.x","volume":"89","author":"EJ Paavonen","year":"2000","unstructured":"Paavonen EJ, Aronen ET, Moilanen I, Piha J, R\u00e4s\u00e4nen E, Tamminen T, et al. Sleep problems of school-aged children: a complementary view. Acta Paediatr. 2000;89(2):223\u20138.","journal-title":"Acta Paediatr"},{"issue":"10","key":"2847_CR6","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/sleep\/30.10.1371","volume":"30","author":"L Fricke-Oerkermann","year":"2007","unstructured":"Fricke-Oerkermann L, Pl\u00fcck J, Schredl M, Heinz K, Mitschke A, Waiter A, et al. Prevalence and course of sleep problems in childhood. Sleep. 2007;30(10):1371\u20137.","journal-title":"Sleep."},{"issue":"5","key":"2847_CR7","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1542\/peds.2008-2005","volume":"124","author":"E Touchette","year":"2009","unstructured":"Touchette E, C\u00f4t\u00e9 SM, Petit D, Liu X, Boivin M, Falissard B, et al. Short nighttime sleep-duration and hyperactivity trajectories in early childhood. Pediatrics. 2009;124(5):e985\u201393.","journal-title":"Pediatrics."},{"issue":"3","key":"2847_CR8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.sleep.2009.03.012","volume":"11","author":"K Velten-Schurian","year":"2010","unstructured":"Velten-Schurian K, Hautzinger M, Poets CF, Schlarb AA. Association between sleep patterns and daytime functioning in children with insomnia: the contribution of parent-reported frequency of night waking and wake time after sleep onset. Sleep Med. 2010;11(3):281\u20138.","journal-title":"Sleep Med"},{"issue":"3 Pt 2","key":"2847_CR9","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2466\/pms.2003.96.3c.1283","volume":"96","author":"C Andreou","year":"2003","unstructured":"Andreou C, Karapetsas A, Agapitou P, Gourgoulianis K. Verbal intelligence and sleep disorders in children with ADHD. Percept Mot Skills. 2003;96(3 Pt 2):1283\u20138.","journal-title":"Percept Mot Skills"},{"issue":"2","key":"2847_CR10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/1467-8624.00414","volume":"73","author":"A Sadeh","year":"2002","unstructured":"Sadeh A, Gruber R, Raviv A. Sleep, neurobehavioral functioning, and behavior problems in school-age children. Child Dev. 2002;73(2):405\u201317.","journal-title":"Child Dev"},{"issue":"1","key":"2847_CR11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1071-9091(96)80028-3","volume":"3","author":"RE Dahl","year":"1996","unstructured":"Dahl RE. The impact of inadequate sleep on children\u2019s daytime cognitive function. Semin Pediatr Neurol. 1996;3(1):44\u201350.","journal-title":"Semin Pediatr Neurol"},{"issue":"11","key":"2847_CR12","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/sleep\/32.11.1449","volume":"32","author":"M Ednick","year":"2009","unstructured":"Ednick M, Cohen AP, McPhail GL, Beebe D, Simakajornboon N, Amin RS. A review of the effects of sleep during the first year of life on cognitive, psychomotor, and temperament development. Sleep. 2009;32(11):1449\u201358.","journal-title":"Sleep."},{"issue":"1","key":"2847_CR13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/phar.1686","volume":"36","author":"AB Blackmer","year":"2016","unstructured":"Blackmer AB, Feinstein JA. Management of Sleep Disorders in children with neurodevelopmental disorders: a review. Pharmacotherapy. 2016;36(1):84\u201398.","journal-title":"Pharmacotherapy."},{"issue":"6","key":"2847_CR14","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/MCP.0b013e328365ab89","volume":"19","author":"M Grigg-Damberger","year":"2013","unstructured":"Grigg-Damberger M, Ralls F. Treatment strategies for complex behavioral insomnia in children with neurodevelopmental disorders. Curr Opin Pulm Med. 2013;19(6):616\u201325.","journal-title":"Curr Opin Pulm Med"},{"issue":"2","key":"2847_CR15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00004703-199304000-00001","volume":"14","author":"MP Whitney","year":"1993","unstructured":"Whitney MP, Thoman EB. Early sleep patterns of premature infants are differentially related to later developmental disabilities. J Dev Behav Pediatr. 1993;14(2):71\u201380.","journal-title":"J Dev Behav Pediatr"},{"issue":"1","key":"2847_CR16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1055\/s-2008-1059638","volume":"12","author":"EB Thoman","year":"1981","unstructured":"Thoman EB, Denenberg VH, Sievel J, Zeidner LP, Becker P. State organization in neonates: developmental inconsistency indicates risk for developmental dysfunction. Neuropediatrics. 1981;12(1):45\u201354.","journal-title":"Neuropediatrics"},{"issue":"4","key":"2847_CR17","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/jpepsy\/jsn013","volume":"33","author":"A Scher","year":"2008","unstructured":"Scher A, Tse L, Hayes VE, Tardif M. Sleep difficulties in infants at risk for developmental delays: a longitudinal study. J Pediatr Psychol. 2008;33(4):396\u2013405.","journal-title":"J Pediatr Psychol"},{"key":"2847_CR18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.sleep.2018.01.008","volume":"44","author":"CR Johnson","year":"2018","unstructured":"Johnson CR, Smith T, DeMand A, Lecavalier L, Evans V, Gurka M, et al. Exploring sleep quality of young children with autism spectrum disorder and disruptive behaviors. Sleep Med. 2018;44:61\u20136.","journal-title":"Sleep Med"},{"key":"2847_CR19","first-page":"1","volume":"118","author":"LI Black","year":"2018","unstructured":"Black LI, Zablotsky B. Chronic school absenteeism among children with selected developmental disabilities: National Health Interview Survey, 2014-2016. Natl Health Stat Report. 2018;118:1\u20137.","journal-title":"Natl Health Stat Report"},{"issue":"1","key":"2847_CR20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-079X.2007.00528.x","volume":"44","author":"MB Wasdell","year":"2008","unstructured":"Wasdell MB, Jan JE, Bomben MM, Freeman RD, Rietveld WJ, Tai J, et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res. 2008;44(1):57\u201364.","journal-title":"J Pineal Res"},{"key":"2847_CR21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ctim.2018.11.003","volume":"42","author":"HM Foley","year":"2019","unstructured":"Foley HM, Steel AE. Adverse events associated with oral administration of melatonin: a critical systematic review of clinical evidence. Complement Ther Med. 2019;42:65\u201381.","journal-title":"Complement Ther Med"},{"issue":"3","key":"2847_CR22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0306-4530(79)90005-2","volume":"4","author":"T Akerstedt","year":"1979","unstructured":"Akerstedt T, Fr\u00f6berg JE, Friberg Y, Wetterberg L. Melatonin excretion, body temperature and subjective arousal during 64 hours of sleep deprivation. Psychoneuroendocrinology. 1979;4(3):219\u201325.","journal-title":"Psychoneuroendocrinology."},{"issue":"2","key":"2847_CR23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2265.1988.tb00263.x","volume":"29","author":"J Arendt","year":"1988","unstructured":"Arendt J. Melatonin. Clin Endocrinol. 1988;29(2):205\u201329.","journal-title":"Clin Endocrinol"},{"issue":"6","key":"2847_CR24","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1210\/jcem-73-6-1276","volume":"73","author":"TA Wehr","year":"1991","unstructured":"Wehr TA. The durations of human melatonin secretion and sleep respond to changes in daylength (photoperiod). J Clin Endocrinol Metab. 1991;73(6):1276\u201380.","journal-title":"J Clin Endocrinol Metab"},{"key":"2847_CR25","first-page":"243","volume":"21","author":"AA Borb\u00e9ly","year":"1986","unstructured":"Borb\u00e9ly AA. Endogenous sleep-substances and sleep regulation. J Neural Transm Suppl. 1986;21:243\u201354.","journal-title":"J Neural Transm Suppl"},{"issue":"2","key":"2847_CR26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1152\/physrev.1989.69.2.605","volume":"69","author":"AA Borb\u00e9ly","year":"1989","unstructured":"Borb\u00e9ly AA, Tobler I. Endogenous sleep-promoting substances and sleep regulation. Physiol Rev. 1989;69(2):605\u201370.","journal-title":"Physiol Rev"},{"issue":"1","key":"2847_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-079X.1993.tb00503.x","volume":"15","author":"D Dawson","year":"1993","unstructured":"Dawson D, Encel N. Melatonin and sleep in humans. J Pineal Res. 1993;15(1):1\u201312.","journal-title":"J Pineal Res"},{"issue":"10","key":"2847_CR28","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1177\/106002809703101015","volume":"31","author":"JE Chase","year":"1997","unstructured":"Chase JE, Gidal BE. Melatonin: therapeutic use in sleep disorders. Ann Pharmacother. 1997;31(10):1218\u201326.","journal-title":"Ann Pharmacother"},{"issue":"6","key":"2847_CR29","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1177\/074873049701200623","volume":"12","author":"T Roth","year":"1997","unstructured":"Roth T, Richardson G. Commentary: is melatonin administration an effective hypnotic? J Biol Rhythm. 1997;12(6):666\u20139.","journal-title":"J Biol Rhythm"},{"issue":"6","key":"2847_CR30","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1177\/074873049701200620","volume":"12","author":"IV Zhdanova","year":"1997","unstructured":"Zhdanova IV, Wurtman RJ. Efficacy of melatonin as a sleep-promoting agent. J Biol Rhythm. 1997;12(6):644\u201350.","journal-title":"J Biol Rhythm"},{"issue":"1","key":"2847_CR31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0899-9007(97)00395-X","volume":"14","author":"D Garfinkel","year":"1998","unstructured":"Garfinkel D, Zisapel N. The use of melatonin for sleep. Nutrition. 1998;14(1):53\u20135.","journal-title":"Nutrition."},{"issue":"4","key":"2847_CR32","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1046\/j.1365-2826.2003.00989.x","volume":"15","author":"C Cajochen","year":"2003","unstructured":"Cajochen C, Kr\u00e4uchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol. 2003;15(4):432\u20137.","journal-title":"J Neuroendocrinol"},{"key":"2847_CR33","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013.","edition":"5"},{"key":"2847_CR34","volume-title":"Aberrant behavior checklist manual","author":"MG Aman","year":"1986","unstructured":"Aman MG, Singh NN. Aberrant behavior checklist manual. New York: Slosson Educational Publications; 1986."},{"key":"2847_CR35","volume-title":"Aberrant behavior checklist\u2014community supplementary manual","author":"MG Aman","year":"1994","unstructured":"Aman MG, Singh NN. Aberrant behavior checklist\u2014community supplementary manual. New York: Slosson Educational Publications; 1994."},{"issue":"4","key":"2847_CR36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0891-4222(96)00015-7","volume":"17","author":"Y Ono","year":"1996","unstructured":"Ono Y. Factor validity and reliability for the aberrant behavior checklist-community in a Japanese population with mental retardation. Res Dev Disabi. 1996;17(4):303\u20139.","journal-title":"Res Dev Disabi"},{"key":"2847_CR37","unstructured":"Medical Dictionary for Regulatory Activities. https:\/\/www.meddra.org\/. Accessed 8 Jan 2019."},{"issue":"10","key":"2847_CR38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1089\/cap.2018.0020","volume":"28","author":"A Maras","year":"2018","unstructured":"Maras A, Schroder CM, Malow BA, Findling RL, Breddy J, Nir T, et al. Long-term efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Child Adolesc Psychopharmacol. 2018;28(10):699\u2013710.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"11","key":"2847_CR39","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jaac.2017.09.414","volume":"56","author":"P Gringras","year":"2017","unstructured":"Gringras P, Nir T, Breddy J, Frydman-Marom A, Findling RL. Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2017;56(11):948\u2013957.e4.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"2847_CR40","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ejpn.2018.05.010","volume":"22","author":"R Kurz","year":"2018","unstructured":"Kurz R, Huemer J, Muchitsch E, Feucht M. Cognitive behavioral therapy for children with autism spectrum disorder: a prospective observational study. Eur J Paediatr Neurol. 2018;22(5):803\u20136.","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"2847_CR41","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/cap.2018.0115","volume":"29","author":"MS Fallah","year":"2019","unstructured":"Fallah MS, Shaikh MR, Neupane B, Rusiecki D, Bennett TA, Beyene J. Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis. J Child Adolesc Psychopharmacol. 2019;29(3):168\u201380.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"1","key":"2847_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/DBP.0000000000000720","volume":"41","author":"C Duh-Leong","year":"2020","unstructured":"Duh-Leong C, Fuller A, Brown NM. Associations between family and community protective factors and attention-deficit\/hyperactivity disorder outcomes among US children. J Dev Behav Pediatr. 2020;41(1):1\u20138.","journal-title":"J Dev Behav Pediatr"},{"issue":"12","key":"2847_CR43","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1136\/archdischild-2017-314181","volume":"103","author":"IS Abdelgadir","year":"2018","unstructured":"Abdelgadir IS, Gordon MA, Akobeng AK. Melatonin for the management of sleep problems in children with neurodevelopmental disorders: a systematic review and meta-analysis. Arch Dis Child. 2018;103(12):1155\u201362.","journal-title":"Arch Dis Child"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02847-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-020-02847-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02847-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T10:36:31Z","timestamp":1723545391000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-020-02847-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2847"],"URL":"https:\/\/doi.org\/10.1186\/s12888-020-02847-y","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]},"assertion":[{"value":"13 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present clinical trial was conducted in accordance with the Helsinki Declaration of 1975 and competent regulations valid in Japan. The protocol and the related informed consent form were approved by the ethics entities at the following 13 medical institutions for 17 participating medical institutions: research ethics committees at Saitama Children\u2019s Medical Center, Hayashi Diabetes Clinic, National Center for Neurology and Psychiatry, National Center for Child Health and Development, Tokyo Metropolitan Children\u2019s Medical Center, Kurume University, and Osaka City General Hospital; institutional review boards at Yamanashi Prefectural Central Hospital, Seikeikai Hospital, Matsuyama Shimin Hospital, Dokkyo University Saitama Medical Center; the institutional review board at Jimbo Orthopedics that covered Ohno Hagukumi Clinic, Hinomine General Ryoiku Center, and Kumamoto Ezuko Ryoiku Medical Center, and the institutional review board at Mizuo Clinic that covered Yokohama Psycho-Developmental Clinic, Oyamadai Suku-suku Clininc, and Mikuri Kids Clinic.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KY reported receiving grant support from Nobelpharma during the conduct of the study. SN reported receiving grant support from Nobelpharma during the conduct of the study. MH reported receiving consulting fees from Nobelpharma during the conduct of the study. KM reported receiving grans from the Japanese Ministry of Health, Labour and Welfare (H29-Seishin-Ippan-001, 19GC1012), the Japanese Ministry of Education, Science, and Technology, and the National Center of Neurology and Psychiatry Intramural Research Grant for Neurological and Psychiatric Disorders, consulting fees from Nobelpharma and Taisho Pharmaceutical, and lecture fees from Eisai, MSD, Takeda Pharmaceutical, Astellas Pharma, and Janssen Pharmaceutical. MF reported receiving grant support from Nobelpharma. HT is an employee of CMIC HOLDINGS. YI, IH, HS, OY are employees of Nobelpharma. YY reported receiving grant support from Nobelpharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"445"}}